Kupfer hat seine beeindruckende Rally fortgesetzt, nachdem das Industriemetall erstmals die Preismarke von 13.000 Dollar pro Tonne überschritten hat. Investoren positionieren sich zunehmend für ein ...
Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of ...
The Punch on MSN
Aviation professionals outline paths to sector recovery
Experts discuss urgent reforms needed for Nigeria's aviation sector, citing poor infrastructure, weak regulation, and ...
At CES 2026, KEENON Robotics, a global leader in service robots, today launched its latest product, the fully autonomous ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
Vor Biopharma Inc. (VOR) stock jumped to a high of $12 yesterday, gaining >20%, but as I discovered to my detriment recently, all is not exactly what it seems at the company. In this post I revisit a ...
Hosted on MSN
Vor Biopharma approves stock option repricing plan
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
GOTHENBURG, SWEDEN and MONTREAL, QC /ACCESS Newswire / January 6, 2026 / Smart Eye (STO:SEYE)(OTC PINK:SMTEF)(FRA:SE9) - Live CES demo shows how 3D depth from a single image sensor can support robust ...
In recent months, Vor Biopharma closed a US$424.83 million shelf registration, repriced employee stock options, and reported positive late-stage clinical data for its autoimmune drug candidate ...
Vor Biopharma (VOR) rose ~17% on Tuesday after J.P. Morgan initiated its coverage with an Overweight recommendation and a Dec. 2026 price target of $43, citing a potential blockbuster status for the ...
The challenges facing biotechs amid the ongoing financial fallout have resulted in the winding down of one US biotech, Vor Bio, and job losses at a clutch of other firms. Cambridge, ...
Investing.com - JPMorgan initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with an Overweight rating and a $43.00 price target, citing the potential of its telitacicept drug. The target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback